RxDoctor Payments Data

Jesse Diaz Correa, MD

Nephrology · Caguas, PRNPI 1609242288

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Merck at 27.0% of the total. Reporting peaked in 2024 at $1,743 and has fallen 57.5% since, to $741 in 2025.

$5,094in general payments, 2019–2025

Across 83 payments — averaging $61.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
  • AstraZeneca$778
  • Boehringer Ingelheim$210
  • Mallinckrodt Hospital Products Inc.$202
  • Vifor Pharma, Inc.$195
  • plus $993 from 14 others

What the payments were for

  • Consulting fees$1,34026%
  • Travel & lodging$1,17523%
  • Food & beverage$2,41247%
  • Education$1683%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,094 in reported general payments places this provider in the 85th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$9,887
Medicare patients
28
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol132$81,330
JardianceEmpagliflozin110$75,517
LokelmaSodium Zirconium Cyclosilicate68$46,328
Lanthanum Carbonate68$40,802
GlyxambiEmpagliflozin/Linagliptin38$27,168
Sevelamer Carbonate181$25,321
Trijardy XrEmpaglifloz/Linaglip/Metformin38$23,806
OzempicSemaglutide15$14,734
JanuviaSitagliptin Phosphate19$10,910
Sodium Polystyrene Sulfonate28$3,454
LantusInsulin Glargine,hum.Rec.Anlog14$1,670
Losartan Potassium175$1,282
Irbesartan58$1,069
SynthroidLevothyroxine Sodium13$988
Nifedipine ErNifedipine46$852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$778$127,658200 claims
Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr$210$126,491186 claims
MerckJanuvia$1,377$10,91019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →